Despite advances in HER targeting, HER2-positive metastatic breast cancer typically progresses. Research has established that the HER2-HER3 complex is the true driver of HER2-amplified cancer and the effective inactivation of this complex is the new bar for novel therapies. In this interactive educational activity, Dr Hurvitz and Dr Tolaney share key data and expert perspectives on recently approved and emerging HER-targeted therapies for metastatic breast cancer.
Sara A. Hurvitz, MD, FACP, Professor of Medicine, Director, Breast Oncology Program, Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Sara M. Tolaney, MD, MPH, Assistant Professor of Medicine, Harvard Medical School, Associate Director, Susan F. Smith Center for Women’s Cancers, Director, Clinical Trials, Breast Oncology, Director of Breast Immunotherapy Clinical Research Dana-Farber Cancer Institute, Boston, Massachusetts.
Click here to participate in this 30-minute CME activity: